ClinicalTrials.gg
RecruitingNCT06330597Updated Mar 26, 2024

NIVIA-Hemodynamics

An observational study in Cardiogenic Shock, Heart Failure and Shock, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shock, Cardiogenic with a site in Canada — 6 open to participants now, 7 under way, none of them phase 3. Shock, Cardiogenic · Canada.

Started
2021
with 1 other
Observational
7 of 13
3 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
University Health Network, Toronto

Among the 13 studies in Shock, Cardiogenic with a site in Canada, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 9th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

6 of the 13 studies in Shock, Cardiogenic with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shock, Cardiogenic with a site in Canada, or all of them as a file.
02

Study summary

This is an investigator-initiated, single-center, single-arm prospective study to compare non-invasive hemodynamic assessment using transthoracic echocardiography (TTE) and lung ultrasound (LUS) and hemodynamic assessment using PAC. Patients who have been hemodynamically assessed using PAC will be invited to participate. Each patient will undergo TTE and LUS immediately after first invasive assessment, and again daily after PAC assessments.

Read the detailed description

Background

Heart Failure

Approximately 600,000 Canadians are living with heart failure (HF) with 50,000 new patients diagnosed each year. Once diagnosed, the median survival for HF patients is 1.7 years for men and 3.2 years for women. As HF progresses, patients experience a worsening in symptom severity, functional capacity, and quality of life. In addition, acute exacerbations of HF is the most frequent cause of unscheduled hospital admissions. Almost 83% of all HF patients will be hospitalized at least once and 43% hospitalized more than three times. However, the mechanisms of HF decompensation are still unclear.

Most drugs (ACE-I/ARB/beta-blockers/MRA) used for the treatment of HF are prescribed because of their ability to improve symptoms or survival. The target doses of these drugs are generally selected on the basis of reported results from randomized controlled trials rather than changes produced in cardiac monitoring of hemodynamics. Interestingly, hemodynamic monitoring has been reportedly indicated in patients where it is difficult to determine their volume status, in addition to those patients refractory to therapy. The ACC/AHA 2013 guidelines3 define the importance of invasive hemodynamic monitoring in patients with:

  • severe clinical decompensation in which therapy is limited by elevated filling pressures, hypoperfusion, and vascular tone
  • persistent severe symptoms despite a trial of recommended therapies
  • the needed or dependency for (or escalation of) pressor and inotropic therapy

Cardiogenic shock

Cardiogenic shock (CS) is a state of profound HF resulting in peripheral organ hypoperfusion, injury and failure. The precipitating events leading to CS are diverse. Patients may experience CS as a slow progression of chronic HF. More frequently however; patients experience CS after an acute cardiac insult such as an acute myocardial infarction, myocarditis or malignant ventricular arrhythmia. It is inevitable that patients who develop CS will die if treatment is not initiated rapidly. In addition, if initial medical therapy fails to maintain adequate cardiac output, initiation of mechanical circulatory support (MCS) represents a life-saving strategy. There has been no established role for the use of invasive hemodynamic measurements in the management of patients with HF. And yet, patients with CS being considered for cardiac transplantation or placement of an MCS device are required to undergo right-heart catheterization using pulmonary artery catheter (PAC), including an assessment of right heart filling pressures, pulmonary artery pressures, left heart filling pressures and cardiac output.

University Health Network (UHN) has the largest and most comprehensive MCS program in Canada. As clinicians working at the Peter Munk Cardiac Centre (PMCC) we are caring for an ever-increasing number of patients with profound refractory cardiogenic shock who require invasive hemodynamic assessment.

Rationale for the study

The majority of patients who present to the CICU require invasive hemodynamic assessment as part of their usual care. To assist in the management of these critically ill patients, the investigators need a complete understanding of the hemodynamic status. Currently, this is usually done invasively by placing a PAC. Alternatively, a non-invasive assessment using transthoracic echocardiography (TTE) can be pursued.

Pulmonary artery Catheter

In early retrospective registries, there was no benefit shown for the use of PAC. However, this had not been studied in patients with CS until recently. In a large retrospective study of CS patients, the use of PAC was associated with improved survival (30% vs 38%). This study provided the basis for the incorporation of PAC into CS treatment algorithms. In addition, the guidelines and scientific statements limited recommendations regarding PAC to use in patients with CS. The hemodynamic data obtained with a PAC can facilitate clinical decision-making and allow customization of a treatment plan through the optimization of medical therapy. However, as with any invasive diagnostic tool, the benefit must be balanced against risks. Complications of PAC include central venous access-related adverse events (\<3.6%), arrhythmias and heart block (0.3% to 3.8%), and pulmonary artery rupture (0.02% to 0.03%).

Transthoracic echocardiography

TTE is a non-invasive ultrasound-based diagnostic tool that has the ability to also evaluate and track both RV and LV hemodynamic status. There is conflicting evidence of the utility of TTE monitoring in reflecting the hemodynamic changes in PAC-derived hemodynamic measurements.

Lung Ultrasound (LUS)

LUS allows for a rapid point-of-care evaluation of a number of conditions, including pulmonary edema, lung consolidation, pleural effusion, and pneumothorax. High intra-rater and inter-rater reproducibility, ease of learning, short exam duration (\<5 min), and the noninvasive nature of this technique makes it an advantageous point-of-care tool. LUS is increasingly used in the acute care setting, and has improved diagnostic accuracy compared with clinical assessment and chest radiography for the identification of a cardiac aetiology in patients presenting to the emergency department with undifferentiated dyspnea. Quantification of B-lines (vertical artefacts that result from an increase in interstitial density) has been shown to be useful for the diagnosis, monitoring, and risk assessment of patients with known or suspected ADHF. Either curvilinear or phased array transducers can be used, typically at an imaging depth of 14-18 cm.

Hypothesis

The investigators hypothesize that non-invasive hemodynamic parameters derived from TTE would be comparable to those obtained invasively by PAC in patient admitted to the CICU. The investigators also hypothesize that there will be a strong correlation between intracardiac pressures and the severity of pulmonary congestion as evaluated by LUS.

03

Conditions studied

  • Cardiogenic Shock
  • Heart Failure
  • Shock
  • Hemodynamic Instability

Keywords

  • Pulmonary Artery Catheter
  • Lung Ultrasound
  • Echocardiography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be composed of patients admitted to the Coronary Intensive Care Unit (CICU) requiring hemodynamic assessment using pulmonary artery catheter (PAC) as standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with admitted to the CICU in whom PAC is inserted as standard of care,

Exclusion criteria

Exclusion Criteria:

  • Enrollment into another trial with an active treatment arm
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients admitted to CICU

    The study population will be composed of patients admitted to the Coronary Intensive Care Unit (CICU) requiring hemodynamic assessment using pulmonary artery catheter (PAC) as standard of care.

    Diagnostic Test: Echocardiography and lung ultrasound

Interventions

  • Diagnostic testEchocardiography and lung ultrasound

    All patients will undergo non-invasive echocardiogram and lung ultrasound at times of assessment of hemodynamic parameters as needed by usual clinical management.

06

What researchers measure

Primary outcomes

  1. Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP.

    To determine whether non-invasive assessment of hemodynamics by echocardiogram are comparable to invasive measurements.

    Time frame: Day 1

Secondary outcomes

  1. Correlation between cardiac output measured by echocardiography (using LVOT diameter and VTI) and by PAC (using thermodilution)

    To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.

    Time frame: Day 1, Day 2

  2. Correlation between right atrial pressure assessed by echocardiography (using IVC diameter and respiratory variation) and by PAC

    To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.

    Time frame: Day 1, Day 2

  3. Correlation between pulmonary pressure assessed by echocardiography (using TR max velocity and estimated RAP) and by PAC

    To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.

    Time frame: Day 1, Day 2

  4. Correlation between pulmonary pressure assessed by echocardiography (using PAT) and by PAC

    To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.

    Time frame: Day 1, Day 2

  5. Correlation between PVR assessed by echocardiography (using PAT) and by PAC

    To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.

    Time frame: Day 1, Day 2

  6. Correlation between right ventricular function assessed by echocardiography (using TAPSE and S') and by PAC (using PAPI and RVSWI)

    To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.

    Time frame: Day 1, Day 2

  7. Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP.

    To determine whether non-invasive assessment of hemodynamics by echocardiogram are comparable to invasive measurements.

    Time frame: Day 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Aug 2024, 37 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 37 months is below that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Mar 26, 2024
StartActual
Jul 17, 2021
Primary completionEst.
Aug 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06330597
Responsible party
Sponsor
First posted
Mar 26, 2024
Start date
Jul 17, 2021
Primary completion
Aug 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 26, 2024

Study contacts

Yishay Szekely, MD
Contact
Yishay.szekely@uhn.ca
416-340-4800 ext. 6805
Filio Billia, MD PhD
principal investigator · UHN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion